The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer

Ann Oncol. 2023 Dec;34(12):1071-1073. doi: 10.1016/j.annonc.2023.10.792.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Female
  • Forecasting
  • Hormones / therapeutic use
  • Humans
  • Receptor, ErbB-2

Substances

  • Hormones
  • Receptor, ErbB-2